Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3
Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics.
👁️ Abeona drops eye gene therapies, pivots to solid tumor T cell therapy: The biotech, which is known for marketing the rare ...
Read the full article on the original site.
Read Full Article